Posted by Michael Wonder on 24 Aug 2018
Kala Pharmaceuticals announces FDA approval of Inveltys for the treatment of post-operative inflammation and pain following ocular surgery
23 August 2018 - First twice daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Kala Pharmaceuticals today announced that the U.S. FDA has approved Invelyts (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.
Invelyts is the first twice daily ocular corticosteroid approved for this indication.
